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ABSTRACT:
Targeted therapies of chronic myeloid leukemia (CML) using tyrosine kinase 
inhibitors (TKI) have profoundly changed the natural history of the disease with a 
major impact on survival.  Molecular monitoring with BCR-ABL quantification shows 
that a status of undetectable molecular residual disease (UMRD) is obtained in a 
significant minority of patients. However, it remains unclear whether these patients 
are definitively cured of their leukemia. Imatinib mesylate withdrawal trials have 
demonstrated the rapid appearance of the malignant clone in the majority of the 
patients whereas some patients remain in a state of UMRD. It has clearly been 
demonstrated that the most primitive stem cells are refractory to all TKIs used in 
clinical practice. In addition, long-term dormancy is one of the most fundamental 
characteristics of hematopoietic stem cells. In this context, we have recently 
undertaken a systematic analysis of the bone marrow stem cell compartment in 
several patients in durable UMRD. We have demonstrated the long-term persistence 
of a considerable amount of BCR-ABL-expressing stem cells, even in the absence 
of relapse. The phenomenon of long-term leukemic stem cell dormancy is of major 
importance in CML and one of the key questions in cancer biology in general. We 
discuss, here, the potential mechanisms, including intrinsic and microenvironmental 
factors, that control the response of leukemic stem cells (LSCs) to targeted 
therapies and potential novel strategies currently in progress with a curative intent. 
Moreover, we propose a molecular evaluation of the residual LSC compartment 
in selected patients in order to develop rational TKI-cessation strategies in CML.
INTRODUCTION
Chronic myeloid leukemia (CML) is a major model 
of oncogenesis involving primitive hematopoietic stem 
cells (HSCs). A unique genetic alteration, the t(9;22)
(q34;q11) translocation that gives rise to the Philadelphia 
chromosome (Ph1) generates the BCR-ABL fusion 
oncoprotein with deregulated tyrosine kinase (TK) 
activity [1]. Genetic instability phenomenon seems to be 
both the cause of Ph1 formation and the consequences of 
BCR-ABL activation [2]. Functional consequences of the 
t(9;22) translocation include an increased cell proliferation, 
a deregulation of cellular adhesion/migration and a 
resistance to apoptosis [3,4]. In the absence of treatment, 
CML classically progresses from chronic phase to blast 
crisis with an intermediate accelerated phase.
During the last three decades, substantial progress 
has been accomplished in the therapy of the disease. 
Allogeneic stem cell transplantation (SCT) was the first 
potentially curative therapy for CML patients in chronic 
phase [5]. However, SCT could not be applied to all 
CML patients because of the lack of HLA-compatible 
donors, but also because of immediate and late toxicities 
due to this process. Interferon-alpha (IFN-α), alone or 
associated with cytarabine, displayed real efficiency in 
a small number of patients, allowing durable complete 
cytogenetic remissions or CCyR (absence of Ph1-positive 
metaphase in conventional cytogenetic analysis) in 
patients responding to treatment [6].
Over the last ten years, small compounds such as 
tyrosine kinase inhibitors (TKIs) have been developed for 
targeted therapy of CML [7]. The introduction of imatinib Oncotarget 2011; 2:  713 - 727 714 www.impactjournals.com/oncotarget
mesylate (IM) has profoundly modified the natural history 
of CML and dramatically improved patient survival [8,9]. 
Nevertheless,  a small percentage of patients develop 
primary or secondary resistance to IM therapy. Biological 
mechanisms of resistance are either BCR-ABL-dependent 
or –independent. Among them, missense mutations, 
identified  within  the  ABL  tyrosine  kinase  (ABL-TK) 
domain, were the most studied. More than 100 mutation 
affecting approximately 70 amino acids were identified 
[10]. The presence of these mutations modifies the protein 
structure and induces a conformational change of the 
kinase domain or disruption of the interactions between 
IM and BCR-ABL (affecting hydrogen or van der Waals 
bonds). Consequently, drug binding is impaired or totally 
abolished by ABL-TK mutations. Second generation TKIs 
such as dasatinib, nilotinib or bosutinib, were designed 
to overcome imatinib resistance [11-13]. These drugs 
are effective on most of the mutants, except for some 
p-loop mutations (moderate or intermediate resistance) 
or the gatekeeper T315I substitution. This mutation, first 
reported by Gorre et al. [14], was shown to confer an 
absolute resistance to all known ATP-competitive BCR-
ABL inhibitors used in clinical practice [15,16]. More 
recently, a pan-BCR-ABL inhibitor TKI (ponatinib) was 
shown to be active against the T315I mutation [17].
In addition to mechanistic aspects of TKI-resistance 
due to the structure of the target oncoprotein, a novel level 
of complexity, inherent to the hierarchical nature of CML 
stem cells has been identified. This refers to the resistance 
of the most primitive HSCs to all TKIs currently used, 
because of three principal causes: their quiescence [18], 
the high levels of BCR-ABL expression [19] or their 
“oncogene-independence” [20]. Recent data showing a 
molecular relapse in the majority of patients upon IM-
discontinuation [21] might suggest the in vivo persistence 
of leukemic stem cells (LSCs).
In the present research perspective, we focus on 
BCR-ABL-expressing hematopoietic stem cells in the 
context of anti-CML treatment. We analyze the question 
of the importance of LSCs in the maintenance of the 
leukemia and the development of resistance to anti-
leukemia therapies. Finally, we discuss the notion of LSC 
persistency and the relationship between the concept of 
cure and the requirement of targeting leukemic stem cells. 
CHRONIC MYELOID LEUKEMIA STEM 
CELLS
Elusive CML stem cell: Which cell is the real 
target?
CML was the first malignancy in which the concept 
of single primitive LSC origin was demonstrated using 
X-chromosome inactivation studies [22]. The finding that 
breakpoints between BCR and ABL genes were identical 
in each cell lineage of a same patient strengthened this 
concept. Although the involvement of T-cells has been 
rarely reported in CML, the occurrence of T-lymphoid 
blast crisis has been clearly documented [23], suggesting 
the involvement of a very primitive progenitor. More 
recently, the existence of stem cells with hemangioblast-
like properties has been reported in several studies [24,25] 
but not confirmed by others [26]. Finally, BCR-ABL gene 
transfer experiments into both murine and human HSCs 
suggested that the expression of this oncogene was 
sufficient to initiate CML [27]. 
As for normal hematopoietic stem cells, CML 
stem cells (in the chronic phase of the disorder) have the 
ability to self-renew and to differentiate in committed 
progenitors, which produce the mature hematopoietic 
cells. Why and how the expression of BCR-ABL does not 
impede the mature cell production is not clear at the present 
time. However, the unperturbed C/EBP (CAAT/enhancer 
binding protein)-alpha expression in chronic phase might 
be involved in this event [28]. CML stem cells have been 
also characterized by the difficulty to examine their in 
vitro behavior as their cell surface markers are very similar 
to normal HSCs, which are enriched in cell populations 
sorted by CD34+CD38-CD71-, and/or Thy1+ markers [29]. 
Classically, studies involving hematopoietic progenitor 
and more primitive stem cell compartments have used 
either clonogenic (colony forming units in culture or 
CFU-C) or long-term culture initiating cell (LTC-IC) 
assays. These biological tests have shown, as expected, 
the presence of Ph1 chromosome in both compartments, 
but interestingly, they revealed the persistence of normal, 
Ph-1 negative stem cells at diagnosis [30] and even at later 
stages of the disease [31].
Although the expansion of the myeloid cell 
compartment occurs in the marrow, CFU-C activity is 
highly increased in peripheral blood at diagnosis [32]. A 
defect of maintenance of Ph1 clone in vitro as compared 
to normal cells was shown by LTC-IC experiments [33]. 
Thus, there is a clear expansion of the more differentiated 
progenitor and myeloid cells in peripheral blood, which 
certainly explains the symptoms of the disease. However, 
the events that lead to leukemic clonal dominance in the 
presence of a less amplified stem cell compartment are not 
established at the present time. Cell cycling studies have 
revealed an increased cycling of clonogenic progenitors in 
CML as compared to normal ones [34]. Analyses of more 
primitive stem cells compartments using immunodeficient 
mouse transplantion assays have not been very successful 
in CML, as they have been in acute myeloid leukemia 
[35,36]. These results were probably due to the difficulties 
of engraftment of such cells in NOD/SCID mouse, either 
due  to  cell  rejection  or  homing  deficiency  of  CML 
progenitors. Therefore, LTC-IC assays using murine 
stromal feeders [37] undoubtedly represent the most 
stringent stem cell assays in human CML.Oncotarget 2011; 2:  713 - 727 715 www.impactjournals.com/oncotarget
LSC quiescence and bone marrow 
microenvironment: A guilty cross-talk?
Long-term preservation of a normal hematopoiesis 
is based on the crucial property of HSCs to escape from 
the cell cycle and to remain quiescent in the bone marrow 
microenvironment (or niche). The quiescence phenomenon 
refers to a reversible cell cycle arrest (G0 phase), whereas 
dormancy concept represents the metabolic state of 
quiescent cells. Although not exactly synonymous, 
quiescence and dormancy are now used indifferently in 
human biology. One of the major characteristics of CML 
stem cells is the presence of highly quiescent primitive 
stem cells, which can be present at diagnosis in peripheral 
blood [38]. The majority of LSCs appears to be in cell 
cycle, whereas normal HSCs are generally quiescent [39]. 
It has been reported that bone marrow microenvironment 
could regulate some HSC properties such as quiescence, 
self-renewal, expansion, and survival [40]. This regulation 
takes place in the osteoblastic and vascular niches [41], 
which might irrespectively control highly quiescent [42] 
and more active HSCs [43]. Recently described nestin-
expressing mesenchymal stem cells could represent 
a unifying concept between osteoblastic and vascular 
niches [44].
Interactions between receptors expressed by HSCs 
and ligands produced by marrow niches have been 
extensively studied [45]. The osteoblastic niche produces 
various soluble ligands that can act as growth factors 
for leukemic cells or recognize specific receptors on the 
surface of HSCs [46]. For example, Tie2 (tyrosine kinase 
with immunoglobulin and EGF homology domains), 
CXCR4 (C-X-C chemokine receptor type 4) and particular 
integrin receptors respectively binds Angiopoetin, SDF-
1α (stromal cell-derived factor-1alpha) and Osteopontin 
produced in the bone marrow niche (Figure 1). Normal HSCs 
expresses the CXCR4 receptor, which recognizes SDF-1α 
(abundantly secreted in the marrow microenvironment), 
allowing the homing of HSCs to bone marrow niches. 
Importantly, the quiescence/cycling balance of normal 
hematopoietic stem cells prevents the exhaustion of the 
stem cell pool and critical components controlling these 
events are progressively being discovered. This is the case 
for JAM-B (junction adhesion molecule B) expressed 
by stromal cells, controlling quiescence [47] and Agrin 
expressed by marrow mesenchymal stem cells (MSCs) 
and endosteal cells, recognizing a specific receptor on the 
most primitive HSC [48].
In CML, the BCR-ABL oncoprotein decreases 
the adhesion of LSCs to the bone marrow environment 
Figure 1: CML stem cells in the context of bone marrow microenvironmental niche. Current data suggest that leukemic 
marrow “niche” contributes to LSC persistency via induction of a quiescence or via protective growth factors (see text).  HSC, hematopoietic 
stem cell; PlGF, placental growth factor; CXCR4, C-X-C chemokine receptor type 4; SDF-1α, stromal cell-derived factor-1alpha; Tie2, 
tyrosine kinase with immunoglobulin and EGF homology domains; ang2, angiopoietin 2; OPN, osteopontin ; TGF-β, Transforming growth 
factor-beta.
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through constitutive phosphorylation of several focal 
adhesion-associated molecules [49]. However, very little 
is known concerning the interactions between CML stem 
cells and the niche components. We have previously 
shown that BCR-ABL-expressing CML cells secreted high 
levels of osteopontin, a component of the hematopoietic 
niche capable to induce HSC quiescence [50] (Figure1). 
It has also been shown that BCR-ABL down-regulates the 
CXCR4 receptor in a TK-dependent manner, affecting the 
migration of leukemic cells towards SDF-1α in vitro, this 
effects being reversed by the use of IM [51]. In a BCR-
ABL-expressing cell line model, it has been suggested 
that the expression of CXCR4 under the influence of IM, 
could generate a migration of the cells escaping apoptosis, 
towards bone marrow niches, this “homing” inducing 
quiescence and CML stem cell survival [52].
The  influence  of  the  bone  marrow  niche  on  the 
behavior of CML stem cells has recently been the subject 
of an intense debate. This microenvironment can certainly 
favor the survival of CML stem cells by providing survival 
and quiescence factors (such as TGF-β) but the notion of 
intrinsic abnormalities of the niche in CML has not been 
extensively studied. Despite the fact they are not a part of 
the malignant Ph1 clone, MSCs from CML patients are 
abnormal and secrete large amounts of PlFG (placental 
growth factor), which promotes marrow angiogenesis 
and CML proliferation [53]. Therefore, the niche might 
provide survival factors to CML stem cells probably in the 
context of LSC/niche cross-talk. Finally, some diffusible 
factors such as TGF-β provided by the microenvironment, 
could activate quiescence pathways on LSC, via nuclear 
translocation of forkhead O transcription factors (FOXO) 
[54].
TARGETING LEUKEMIC STEM CELLS: 
REQUIRED FOR CURE?
Although TKI therapy (IM and 2nd generation 
inhibitors) demonstrated great efficacy in most chronic 
phase  CML  patients,  data  from  first  line  IM  trials 
show that 15% of patients resist to the therapy [9]. 
Classically, the mechanisms of resistance/refractoriness 
are drug dependant, BCR-ABL dependent or BCR-ABL 
independent (Table 1) [55]. A second level of resistance is 
now known to occur in the very primitive stem cell level; 
a finding documented in vitro and in vivo as observed in 
IM-cessation trials.
TABLE  1: Mechanisms of CML resistance to imatinib
Imatinib-dependent  (decreased intracellular level)
1. Increased drug efflux (over-expression of ABCB1 and ABCG2 transporters)
2. Decreased drug influx (under-expresionof OCT1 transporters)
3. Imatinib plasma sequestration
BCR-ABL-dependent
1. BCR-ABL gene amplification 
2. BCR-ABL kinase domaine missense mutations
ATP binding site or p-loop (e.g. G250E, Q252E/H,  Y253F/H, E255K/V…..)
Imatinib binding sites (e.g. T315I, F317L,….)
Activation loop (e.g. M351T,  F359C/V,….)
Catalytic loop (e.g. H396P/R,….)
BCR-ABL-independent
1. Genetic instability
2. Leukemic stem cell quiescence
3. Contribution of the leukemic stem cell niche
4. Alternative signaling pathways (e.g. independence from BCR-ABL “oncogene 
addiction”)Oncotarget 2011; 2:  713 - 727 717 www.impactjournals.com/oncotarget
CML stem cells are refractory to TKI therapies 
In vitro, it has been shown that the most primitive 
quiescent LSCs are intrinsically refractory to imatinib 
[18,56], dasatinib [57], nilotinib [58] and bosutinib [59]. 
However, it should be noted that dasatinib retains a better 
efficacy  in  the  stem  cell  compartment  than  imatinib. 
Multiple mechanisms can play a role in the innate 
resistance of primitive HSCs toward TKIs including 
down-regulation of OCT-1 transporter (allowing IM 
transport inside cells), up-regulation of ABCB1 (MDR1) 
and ABCG2  efflux  drug  transporters  or  high  levels  of 
BCR-ABL protein present in these cells [60,61]. In a 
transgenic mice model, restricting the expression of BCR-
ABL in stem cell antigen 1 (Sca1)-positive cells, the 
authors generated a murine CML intrinsically resistant 
to IM [62]. Some unknown epigenetic changes induced 
in the context of CML cells could explain these findings 
and remain to be explored. In addition, a recent work has 
shown that the survival of Ph1-positive LSCs might be 
independent of the BCR-ABL kinase activity [20].
ABL-TK mutation in CML stem cells
Early clinical observations in CML patients have 
suggested that ABL-TK mutations can occur in Ph1 stem 
cells. We have demonstrated, in vitro, the occurrence of 
ABL-TK mutations (Q252E and M351T) in CD34+CD38- 
cell populations and their LTC-IC-derived progeny [63]. 
These results were later confirmed in CD34+ cells from 
CML patients using subcloning-PCR [64]. Consequently, 
it is now clear that BCR-ABL mutations arise in the 
primitive hematopoietic compartment. Concerning 
the T315I gatekeeper mutation, we have performed an 
extensive analysis of CFU-C and LTC-IC assays on bone 
marrow and blood cells from a CML patient using an allele-
specific  RT-qPCR  (Reverse  transcription-quantitative 
real-time PCR) [65]. We clearly demonstrated that this 
substitution has occurred in a very primitive Ph1 stem 
cell without altering its myeloid and erythroid terminal 
differentiation potential [31].
Overall, these data suggest that primitive quiescent 
CML stem cells (with or without ABL-K mutations) are 
protected  from  targeted  therapies  under  the  influence 
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Figure 2: Several levels of residual disease in CML (adapted from Goldman, 2007, Blood, 110, 2828-37). On the same 
scale are presented together the BCR-ABL/ABL ratios and the estimated number of leukemic cells at diagnosis. The time of diagnosis, 
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of cell-autonomous pathways or external cues such as 
niche-driven mechanisms, leading to the accumulation 
of a genuine leukemic reservoir. In addition, recent data 
concerning the “oncogene-independence” of these cells 
suggest  that  TKIs  alone,  although  extremely  efficient 
in the bulk of the disease burden, will not theoretically 
lead to a complete eradication of the disease. The current 
development of strategies targeting CML leukemic stem 
cells using specific pathways is based on this concept.
TARGETING STEM CELL MOLECULAR 
PATHWAYS 
Many signaling pathways are involved in the basic 
properties of HSCs, some of them could be specific of 
LSCs. Consequently they represent a target for potential 
therapy against CML stem cells [66,67].
Some signaling pathways common to leukemic 
and normal HSCs
The canonical inter-connected Wnt/β-catenin, Sonic 
Hedgehog and Notch signaling pathways play crucial roles 
in the maintenance of stem cell functions. Wnt/β-catenin 
pathway is required for survival and long-term renewal 
of CML stem cells [68,69]. In the blast crisis phase of 
the disease, it has been suggested that hematopoietic 
progenitors could re-acquire some stemness properties 
(e.g. self-renewing) through an activation of β-catenin 
[70]. Recently, Hes1 (a Notch target gene) was shown 
to maintain CML stem cell self-renewal and promote 
blast crisis transformation [71]. The importance of the 
Sonic Hedgehog pathway has also been demonstrated in 
LSC renewal and CML progression. [72,73]. Moreover, 
the hematopoietic niche could regulate Notch and Wnt 
signaling pathways [42,74]. The well-known PML tumor 
suppressor involved in promyelocytic leukemia through 
the PML-RARα rearrangement has also been shown to 
be required for the maintenance of normal HSCs and 
CML stem cells [75]. Targeted therapy against normal and 
leukemic stem cells could now be considered since many 
critical signaling pathways involved in the maintenance of 
stemness can be inhibited (Table 2).
Signaling pathways specific to LSCs
Arachidonate 5-lipoxygenase (Alox5) has been 
shown to be indispensable for the survival, proliferation 
and differentiation of CML stem cells. In addition, the 
inhibition  of Alox5  specifically  impairs  LSC  functions 
and does not affect normal HSCs [76]. The AHI-1 
(abelson helper integration site 1) oncogene might also 
be a potential LSC target since it appears over-expressed 
in CML stem cells and enhance BCR-ABL effect on cell 
growth [77]. In vitro, the suppression of AHI-1 over-
TABLE  2: targeting some critical stem cell signaling pathways
Pathway Target Inhibitor Current clinical use
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expression was related to a reduction of LSC growth 
autonomy. Moreover, AHI-1 was found to interact not 
only with BCR-ABL but also with the JAK2/STAT5 
pathway.  In  another  field,  it  has  been  shown  that  the 
inhibition of the Hsp90 protein (a chaperone for BCR-
ABL) could target CML stem cell [78]. Finally, recent 
publications  highlight  the  benefit  of  targeting  STAT5 
(signal transducers and activators of transcription 5) since 
this pathway has been clearly involved in leukemia cell 
survival and TKI resistance [79,80]. However, to be used 
as therapy, the effects of STAT5 inhibitors on the LSC 
compartment have to be verified [81].
DYNAMICS OF THE RESPONSE TO 
TYROSINE KINASE INHIBITORS
The hematological follow-up of CML patients on 
TKI treatment is classically based on blood cell counts 
(estimation of the hematologic response), cytogenetic 
analysis by the determination of the percentage of Ph1-
positive metaphases (evaluation of the cytogenetic 
response)  and  quantification  of  BCR-ABL mRNA 
transcripts (assessment of the molecular response). 
International recommendations have determined the 
appropriate periods of testing in order to ascertain the 
status of the response (optimal and suboptimal responses, 
failure, warnings) [82]. Moreover, a screening of ABL-TK 
mutations is mandatory in case of TKI failure (primary 
resistance) or loss of therapy response (secondary 
resistance) [83].
Monitoring of treatment response 
 RT-qPCR is the most sensitive test for the 
quantification of BCR-ABL mRNA transcripts. Laboratory 
protocols are now properly standardized [84-86] and 
international reference controls have been elaborated 
[87]. A BCR-ABL/“control gene” ratio is determined with 
usually ABL as the control gene. The main objective of 
these collaborative studies was to establish a concordant 
major molecular response (MMR) value corresponding 
to a BCR-ABL/ABL ratio of 0.1%. Moreover, for TKI 
good responders, RT-qPCR remains the ultimate test to 
follow the residual disease. It must be underlined that the 
limit of detection of BCR-ABL quantification protocols is 
around 10-5 (BCR-ABL/ABL ratio ~ 0.001%). The regular 
quantification of the BCR-ABL mRNA transcript level, 
evaluated by a BCR-ABL/ABL ratio every 3 months allows 
the determination of kinetics of CML response throughout 
the disease monitoring.
A schematic representation of decreasing CML 
residual disease has been proposed [88]. It integrates the 
BCR-ABL/ABL ratios, the estimated total-body leukemic 
cell burden, the CCyR, and the MMR (Figure 2). The 
absence of detectable BCR-ABL mRNA transcript from 
blood and/or marrow samples using RNA samples of 
adequate quality characterizes an undetectable molecular 
residual disease or UMRD (also named complete 
molecular response). It is noticeable that the non-detection 
of BCR-ABL mRNA transcript does not mean the complete 
eradication of leukemic cells since up to one million CML 
hematopoietic cells could persist in the patient’s body in 
the UMRD context.
Mathematical models of treatment monitoring
These models are based on the kinetics of BCR-
ABL mRNA transcripts determined during molecular 
monitoring of CML patients. For most patients responding 
to imatinib, a biphasic BCR-ABL/ABL exponential decrease 
is typically observed. Mathematical modeling of such 
observations related to the hematopoietic differentiation 
process (from hematopoietic stem cells to mature cells) 
has been elaborated [89,90]. The two slopes of the BCR-
ABL mRNA decline curves (3-4 log reduction) could be 
consistent with the eradication of differentiated mature 
CML cells (fast slope) and leukemic progenitors (slow 
slope). Therefore, residual leukemic cells in the UMRD 
context are likely to correspond to CML stem cells. Using 
the same model, it was recently suggested that sustained 
TKI therapy might reduce (in part and in some cases) the 
leukemic stem cell burden [91]. In addition, these models 
propose some hypotheses concerning the relationship 
between leukemic progenitors and blast crisis [92], the 
eradication of CML stem cells [91,93], and the importance 
of stem cell quiescence on the success of TKI therapy [94]. 
However, data concerning the stem cell compartment have 
to be verified on biological experiments.
LEUKEMIC STEM CELL PERSISTENCY 
AND CURE OF CML
Data from patients treated with allogeneic SCT, 
which is considered as the only “curative” therapy of 
CML, show that late relapses can occur up to 15 years 
after transplants. An unbalanced relationship between 
LSCs and graft versus leukemia effect, which might be 
operational in a fraction of LSC, could be the cause of 
late  relapses  [95].  Concerning  IFN-α  or  TKIs  (mainly 
imatinib), several treatment discontinuation trials have 
been performed. Although data from IM discontinuation 
trials suggest that some patients are disease-free and 
off-therapy  for  approximately  3-4  years,  a  significant 
percentage of patients relapsed (molecular or cytogenetic 
relapses) after the cessation of the therapy. Overall, these 
data point to a likely role of CML stem cells in the relapse 
occurrence. Therefore, investigation of the stem cell 
compartment in these patients seems to be warranted, in 
order to determine 1) the persistence of these cells in the 
UMRD context and 2) their relevance with regard to the Oncotarget 2011; 2:  713 - 727 720 www.impactjournals.com/oncotarget
occurrence of the relapse. This approach appears crucial to 
design rational algorithms of TKI-therapy discontinuation 
trials [96].
Therapy discontinuation trials
For IFN-α therapy, clinical experiences have shown 
that a minority of CML patients achieved a long-term 
period of CCyR. In this population, it has been reported 
that some patients who stopped their treatment maintained 
a durable CCyR [97]. In this work, one patient who was in 
major cytogenetic response (<35% Ph1 chromosomes) at 
the time of cessation maintained his remission status after 
more than 7 years after stopping IFN-α. Although very 
probable, the presence of BCR-ABL-expressing LSC was 
not evaluated in these early studies. It is important to note 
that, before the TKI era, IFN-α therapy has induced in a 
few patients a prolonged CCyR that have persisted after 
the discontinuation of the treatment [98]. Thus, some LSC 
could be efficiently controlled in a “dormant” or “inactive” 
state in some patients treated with IFN-α alone (but not in 
UMRD state), suggesting a particular role for IFN-α in 
the therapy of CML. It has been reported that IFN-α could 
be more active than imatinib against leukemic progenitors 
[99]. Furthermore, in vivo mouse models are suggestive 
of its potential to activate quiescent hematopoietic stem 
cells [100]. A two-step strategy combining the activation 
of dormant LSCs (by IFN-α) and the destruction of re-
cycling cells (by IM) has been suggested [101].
More recently, several clinical pilot studies of 
imatinib cessation for patients who achieved sustained 
UMRD have been published [102-107]. Overall, these 
trials showed that UMRD persists in less than half of 
patients. Consequently, a cytogenetic or molecular 
relapse was observed in the remaining. Moreover, the 
great majority of the patients had previously treated with 
IFN-α. The French STIM (STop IMatinib) trial recently 
reported the results of imatinib cessation in patients with 
sustained UMRD for 2 years or more [21]. In this work, 
the molecular relapse-free survival was 41% at 1 year 
showing that a molecular relapse occurred in a significant 
proportion of patients. In this study, no difference was 
observed according to the use or not of IFN-α as first-line 
therapy. These clinical trials could not only support the in 
vivo existence of LSCs believed to be responsible for the 
molecular relapse, but also address the issue of whether 
the patients who did not relapse are definitely cured or not.
Persistence of leukemic stem cells
UMRD or complete molecular remission have been 
defined as non-detection of BCR-ABL mRNA transcript in 
the peripheral blood by RT-qPCR and/or nested RT-PCR 
[82]. This assumption is mainly related to the sensitivity 
of the method and the characteristics of the biological 
sample. Detection at the genomic level of the BCR-
ABL rearrangement in some patients in UMRD after IM 
therapy or SCT demonstrated the presence of residual 
leukemic cells not detected by RT-PCR experiments 
[108,109]. These data show that leukemic cells are not 
entirely eradicated by TKIs. It must be noted that, in these 
experiments,  BCR-ABL positive DNA was detected in 
peripheral blood. In addition, the stem cell compartment 
was not analyzed. Moreover, RT-qPCR experiments 
on purified sorted cells from CML patients treated with 
imatinib showed the elimination of CML progenitors 
within one year but the retention of the LSC population 
[110].
Ten years ago, (based on the observation of patients 
in sustained CCyR following IFN-α or allogeneic SCT), 
we postulated that the BCR-ABL rearrangement could 
persist unexpressed in dormant cells [111]. The persistence 
of such dormant leukemic progenitors in CCyR induced 
after IFN-α  therapy had previously been demonstrated 
using RT-PCR experiments on CFU-Cs, [112]. More 
recent studies in CML patients who achieved CCyR 
following TKI therapy (mainly imatinib, but also dasatinib 
or bosutinib) have also demonstrated the persistence 
of Ph1 stem cells [113-115]. These experiments were 
performed by fluorescent in situ hybridization (FISH) on 
CD34+ fraction [113,114], CD34+ CD38- cells [115] or 
CFU-Cs and LTC-IC [113] populations. In these studies, 
the presence of persistent LSCs was somewhat expected 
as there was no evidence of molecular eradication of the 
leukemia.
The UMRD status can now be obtained in CML 
patients treated with TKI and, have also been observed 
in historical cohorts, in a minority of patients treated with 
IFN-α.  The  question  of  whether  BCR-ABL-expressing 
LSCs persist in these populations has been unexplored so 
far. We have analyzed the presence of BCR-ABL-expressing 
hematopoietic stem cells in bone marrow samples from 
six CML patients with undetectable BCR-ABL transcript 
in their peripheral blood for more than 3 years [96]. The 
experimental design was based on CFU-C and LTC-
IC assays according to a common protocol. Long-term 
cultures were carried out either on classical murine MS-5 
feeder cells or on HOXB4-expressing MS-5 stromal cells 
[37,116]. Approximately 20 individual colonies and up to 
20 pools of 10 colonies were plucked from clonogenic 
assays at day 0 and from LTC-IC-derived progenitors at 
week 5. Individual and pooled colonies were tested for the 
presence of BCR-ABL mRNA by RT-qPCR and controlled 
by nested RT-PCR. Using this strategy, we detected a 
variable percentage of BCR-ABL-expressing stem cells in 
all patients analyzed. Interestingly, these primitive HSCs 
did not produce any detectable BCR-ABL transcript in the 
peripheral blood, suggestive of their quiescent status in 
vivo, even in patients in whom the anti-leukemic therapy 
had been stopped for > 11 years. It is noticeable that a 
greater percentage of BCR-ABL-expressing stem cells Oncotarget 2011; 2:  713 - 727 721 www.impactjournals.com/oncotarget
was  observed  in  patients  previously  treated  by  IFN-α 
alone as compared with those treated by IM after IFN-α 
failure. These data could be indicative of a more effective 
eradication of the stem cell compartment in the latter case, 
but they must be confirmed on a larger series of patients. 
Finally, the major involvement of marrow LSCs in these 
patients (2000 CFU-Cs or LTC-ICs analyzed and only a 
fraction of the marrow cells assayed) suggest the presence 
of a highly active inhibitory process in the bone marrow 
niches, maintaining these stem cells in a long-term 
dormancy state.
CONCLUSIONS 
TKI therapy has dramatically improved the overall 
survival in CML and a minority of patients achieved a 
sustained state of UMRD. In this context, for clinicians, 
patients and socio-economical reasons, the recurrent 
question remains the discontinuation of TKI therapies. 
Clinical data show that half of the patients will develop 
a molecular relapse within a few months after imatinib 
cessation. Despite the fact that the decision of IM-
discontinuation was done without the assessment of the 
LSC content in these patients, the leukemic stem cells 
persistency with active stem cells is highly probable in 
these patients. However, in the remaining 40% of patients 
who did not relapse, the evaluation of the LSC persistency 
might be of major interest. Consequently, in the context 
of molecular remission, the characterization of LSCs by 
functional assays could be considered in clinical practice. 
Overall, these data raise some critical questions.
1 - Predictive role of stem cell tests following 
targeted therapies
We have developed a screening procedure based on 
the detection of BCR-ABL mRNA transcripts in CFU-Cs 
and LTC-ICs by RT-qPCR that appears more adapted than 
FISH to analyze large amount of hematopoietic colonies. 
To ensure the reliability of the test, RT-qPCR experiments 
have to be carefully controlled at each step of the 
CML patient in sustained UMRD 
induced by TKI
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Figure 3: Experimental strategy to analyze the presence of BCR-ABL-expressing cells in progenitor and stem cell 
compartments. UMRD, undetectable molecular residual disease; CFU-C, colony forming unit-cell; LTC-IC, long-term culture-initiating 
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amplification process (presence of positive and negative 
controls). However, the method can underestimate the 
number of BCR-ABL-expressing stem cells because 
of to the small number of hematopoietic cells analyzed 
(500-4000, according to the size of the colonies) and a 
variable transcription of BCR-ABL in Ph1 hematopoietic 
progenitors  [117].  To  be  more  efficient,  we  recently 
modified  the  procedure  to  convert  it  in  a  step-by-step 
protocol (Figure 3). All LTC-IC assays are now performed 
on MS-5/HOXB4 stromal feeders in order to increase the 
sensitivity of the test. In addition, LTC-IC experiments are 
only carried out when the preliminary CFU-C assays are 
negative (absence of BCR-ABL-expressing progenitors). 
In the presence of negative CFU-C and LTC-IC assays, 
in vivo xenogeneic transplantations in immunodeficient 
NOG (NOD/Shi-scid/IL-2Rγnull) mice can be considered. 
In the light of clinical data and stem cell tests, it remains 
to be established whether the persistency of residual BCR-
ABL-expressing stem cells (cycling or quiescent) in CML 
patients in sustained UMRD represents or not a potential 
risk of disease recurrence.
2 - Can TKIs alone cure CML patients?
Before discussing this issue, we have to precise 
the notion of cure in CML. We can distinguish the 
“clinical cure” defined by the absence of relapse from 
the “biological cure” defined by the absence of leukemic 
cells (including LSCs). This assertion is supported by 
our data showing that some patients who appeared 
clinically “cured” had persistent LSCs. The detection of 
BCR-ABL-expressing clonogenic and LTC-IC-derived 
progenitors in patients with sustained UMRD might 
confirm the presence of a significant quiescent CML stem 
cell compartment. Moreover, it has been shown that the 
most primitive LSCs are intrinsically refractory to all 
TKIs used in clinical practice. In addition, TKIs might 
cause an osteogenic niche homing of LSCs increasing the 
quiescent CML stem cell burden. In this context, the use 
of IFN-α (to awake dormant LSCs) could be of interest. 
Conversely, some studies hypothesize that long-term TKI 
therapy (especially with the 2nd generation drugs) could 
significantly reduce the malignant stem cell compartment. 
It has also been reported that it was not necessary to kill 
the last leukemic cell [118]. Nevertheless, TKI therapy 
alone seems unlikely to be fully curative, and a risk of 
relapse subsists even in sustained UMRD. Consequently, 
in this context, the molecular residual disease has to be 
thoroughly monitored. In this situation, positive and 
negative RT-qPCR areas can be distinguished (Figure 
2).  The  first  one  corresponds  to  a  “decision-making” 
zone and is related to ELN (European leukemia Net) 
recommendations. The second is consistent with a non-
decisional zone in which the correlation between the 
leukemic stem cell persistency and relapse (on- or off-TKI 
therapy) remains to be evaluated.
3 - Leukemic stem cells as a target
Theoretically, to eradicate a leukemic process, it is 
mandatory to eliminate the last leukemic stem cell; this 
might be the definitive objective in CML [119]. Nowadays, 
many signaling pathways involved in hematopoietic 
stem cell maintenance have been described, and a few 
inhibitors (some in clinical use) have been identified. It is 
then possible to affect more or less specifically LSCs. The 
option of targeting CML stem cells in patients in sustained 
UMRD must be considered with precaution because of the 
probable side effects of the drugs. In this circumstance, a 
prior evaluation of the LSC compartment could be useful.
Despite the great success of TKI therapies, many 
points  have  to  be  clarified  such  as  the  mechanisms  of 
long-term leukemic stem cell dormancy, the role of 
an immunomodulatory effect of the treatments, the 
relation between CML stem cells and the bone marrow 
microenvironment. Moreover, the analysis of BCR-ABL-
expressing stem cells in CML patients with sustained 
UMRD induced by 2nd generation TKIs must be performed, 
as these drugs generate molecular responses more rapidly 
than imatinib.
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